Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894

PHIO•2026-08-11

U.S. patent allowance for PH-894

Phio Pharmaceuticals received a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL siRNA designed to selectively silence BRD4.

The company said the patent strengthens IP protection for PH-894’s chemical structure, genetic sequencing, and potential uses in proliferative and infectious diseases.

Phio said its patent portfolio totals 54 issued patents across INTASYL chemistry, gene targets, and therapeutic applications.

Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894

U.S. patent allowance for PH-894

Related News

Bruker Announces Strategic Collaboration With Atinary Technologies To Advance Self-Driving Laboratories

Neurogene Q2 adjusted loss per share misses estimates on employee costs

Eltek updates financial calendar with Q2 2026 earnings release and conference call schedule

Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights

Littelfuse appoints Plexus CEO Todd Kelsey to board, names him to compensation panel